Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study

Table 1 Association between the clinicopathologic characteristics and the SH3PXD2B expression levels in HCC patients (n = 89)

Characteristics	n	SH3PXD2B expression		χ²	P value
Characteristics	n	High	Low	χ²	P value
Gender
Male	77	35	42	0.691	0.406
Female	12	7	5
Age (years)
≥ 60	23	8	15	1.916	0.166
< 60	66	34	32
HBsAg
Positive	71	39	32	8.436	0.004
Negative	18	3	15
Liver fibrosis
0	2	2	0	2.535	0.638
1	19	8	11
2	14	7	7
3	7	3	4
4	47	22	25
Liver cirrhosis
Yes	47	22	25	0.006	0.939
No	42	20	22
Tumor size (cm)
≥ 5	56	27	29	0.063	0.801
< 5	33	15	18
Tumor number
Single	66	31	35	0.005	0.944
Multiple	23	11	12
Microvascular invasion
M0	36	17	19	0.860	0.651
M1	37	19	18
M2	16	6	10
Macrovasucular invasion
Yes	16	9	7	0.642	0.432
No	73	33	40
Edmondson–Steiner Grade
I–II	25	7	18	5.138	0.023
III–IV	64	35	29
TNM stage
I–II	70	29	41	4.369	0.037
III–IV	19	13	6
Ki-67
≥ 30%	47	27	20	4.203	0.040
< 30%	42	15	27
AFP
≥ 400 ng/ml	36	22	14	4.700	0.030
< 400 ng/ml	53	20	33
CA125
≥ 35U/ml	7	1	6	3.301	0.114
< 35U/ml	82	41	41
CA199
> 35U/ml	8	2	6	1.737	0.273
≤ 35U/ml	81	40	41
TP53 mutation
Yes	52	23	29	0.440	0.507
No	37	19	18

ISSN: 1755-8794